High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088)

HIV-infected individuals have poor responses to inactivated influenza vaccines. To evaluate the potential role of regulatory T (Treg) and B cells (Breg), we analyzed their correlation with humoral and cell-mediated immune (CMI) responses to pandemic influenza (pH1N1) monovalent vaccine in HIV-infected children and youth. Seventy-four HIV-infected, 4- to 25-y old participants in a 2-dose pH1N1 vaccine study had circulating and pH1N1-stimulated Treg and Breg measured by flow cytometry at baseline, post-dose 1 and post-dose 2. Concomitantly, CMI was measured by ELISPOT and flow cytometry; and antibodies by hemagglutination inhibition (HAI). At baseline, most of the participants had pH1N1-specific IFNγ ELISPOT responses, whose magnitude positively correlated with the baseline pH1N1, but not with seasonal H1N1 HAI titers. pH1N1-specific IFNγ ELISPOT responses did not change post-dose 1 and significantly decreased post-dose 2. In contrast, circulating CD4+CD25+% and CD4+FOXP3+% Treg increased after vaccination. The decrease in IFNγ ELISPOT results was marginally associated with higher pH1N1-specific CD19+FOXP3+ and CD4+TGFβ+% Breg and Treg, respectively. In contrast, increases in HAI titers post-dose 1 were associated with significantly higher circulating CD19+CD25+% post-dose 1, whereas increases in IFNγ ELISPOT results post-dose 1 were associated with higher circulating CD4+/C8+CD25+FOXP3+%. In conclusion, in HIV-infected children and youth, influenza-specific Treg and Breg may contribute to poor responses to vaccination. However, robust humoral and CMI responses to vaccination may result in increased circulating Treg and/or Breg, establishing a feed-back mechanism.

[1]  S. Shulman.  Children's Memorial Hospital of Chicago , 2014 .

[2]  E. Stupka,et al.  A novel function for FOXP3 in humans: intrinsic regulation of conventional T cells. , 2013, Blood.

[3]  S. Spector,et al.  Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. , 2012, The Journal of infectious diseases.

[4]  S. Jeganathan,et al.  Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV‐1‐infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere , 2012, HIV medicine.

[5]  A. Rieger,et al.  Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals , 2012, PloS one.

[6]  C. Chougnet,et al.  cAMP during HIV infection: friend or foe? , 2012, AIDS research and human retroviruses.

[7]  A. Monto,et al.  Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. , 2011, The Journal of infectious diseases.

[8]  C. Fichtenbaum,et al.  Frequency of Circulating Regulatory T Cells Increases during Chronic HIV Infection and Is Largely Controlled by Highly Active Antiretroviral Therapy , 2011, PloS one.

[9]  R. Rappuoli,et al.  Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children , 2011, The Pediatric infectious disease journal.

[10]  L. Aurpibul,et al.  Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children. , 2011, Vaccine.

[11]  J. Wood,et al.  Serological response to trivalent inactive influenza vaccine in HIV-infected children with different immunologic status. , 2011, Vaccine.

[12]  J. Singer,et al.  Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults , 2011, PloS one.

[13]  Jeffrey N. Martin,et al.  A Low T Regulatory Cell Response May Contribute to Both Viral Control and Generalized Immune Activation in HIV Controllers , 2011, PloS one.

[14]  E. S. St. Clair,et al.  Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. , 2011, Blood.

[15]  R. Gelman,et al.  Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. , 2010, Journal of immunological methods.

[16]  I. Frank,et al.  Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals , 2010, AIDS.

[17]  Keitaro Tanaka,et al.  Evaluation of seasonal influenza vaccination effectiveness based on antibody efficacy among the institutionalized elderly in Japan. , 2010, Vaccine.

[18]  M. Levin,et al.  T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines. , 2010, AIDS research and human retroviruses.

[19]  L. Hammitt,et al.  Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine. , 2009, Vaccine.

[20]  P. Defechereux,et al.  Optimization and Limitations of Use of Cryopreserved Peripheral Blood Mononuclear Cells for Functional and Phenotypic T-Cell Characterization , 2009, Clinical and Vaccine Immunology.

[21]  C. Ewen,et al.  Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. , 2009, Vaccine.

[22]  A. Ho,et al.  Induction of CD4+ T-cell anergy and apoptosis by activated human B cells. , 2008, Blood.

[23]  R. Walker,et al.  Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. , 2008, Vaccine.

[24]  W. Gruber,et al.  Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children , 2008, Clinical and Vaccine Immunology.

[25]  I. James,et al.  Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy , 2007, AIDS.

[26]  R. Couch,et al.  Control of mucosal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes , 2007, Respiratory research.

[27]  M. McElrath,et al.  Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. , 2007, Journal of immunological methods.

[28]  J. Leventhal,et al.  Targeting Acute Allograft Rejection by Immunotherapy With Ex Vivo-Expanded Natural CD4+CD25+ Regulatory T Cells , 2006, Transplantation.

[29]  D. Lewis,et al.  Cellular Immune Responses in Children and Adults Receiving Inactivated or Live Attenuated Influenza Vaccines , 2006, Journal of Virology.

[30]  A. Thomson,et al.  Regulated Compartmentalization of Programmed Cell Death-1 Discriminates CD4+CD25+ Resting Regulatory T Cells from Activated T Cells1 , 2006, The Journal of Immunology.

[31]  P. Doherty,et al.  Cell-mediated Protection in Influenza Infection , 2006, Emerging infectious diseases.

[32]  S. Ziegler,et al.  The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. , 2005, The Journal of clinical investigation.

[33]  M. Lejeune,et al.  Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin’s lymphoma , 2005, Annals of Hematology.

[34]  D. Follmann,et al.  Compromised B cell responses to influenza vaccination in HIV-infected individuals. , 2005, The Journal of infectious diseases.

[35]  S. Ziegler,et al.  De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  N. Shire,et al.  Cutting Edge: The Prevalence of Regulatory T Cells in Lymphoid Tissue Is Correlated with Viral Load in HIV-Infected Patients 1 , 2005, The Journal of Immunology.

[37]  O. Yang,et al.  Decreased perforin and granzyme B expression in senescent HIV-1-specific cytotoxic T lymphocytes. , 2005, Virology.

[38]  S. Ziegler,et al.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. , 2003, The Journal of clinical investigation.

[39]  S. Gravenstein,et al.  Granzyme B: a marker of risk for influenza in institutionalized older adults. , 2001, Vaccine.

[40]  Lihan K. Yan,et al.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. , 2000, The Journal of infectious diseases.

[41]  M. Pinkoski,et al.  The cell-mediated cytotoxic response to influenza vaccination using an assay for granzyme B activity. , 1996, Journal of immunological methods.

[42]  L. Eberly,et al.  Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  A. Akbar,et al.  Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. , 2006, The Journal of clinical investigation.

[44]  N. Shire,et al.  The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. , 2005, Journal of Immunology.

[45]  E. Schmitt,et al.  The Regulatory T Cell Family: Distinct Subsets and their Interrelations , 2003 .